IOV-4001

Iovance Biotherapeutics, Inc. · Phase 1 active Biologic

At a glance

Generic name	IOV-4001
Sponsor	Iovance Biotherapeutics, Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IOV-4001 CI brief — competitive landscape report
IOV-4001 updates RSS · CI watch RSS
Iovance Biotherapeutics, Inc. portfolio CI